Chemotherapy-Induced Nausea and Vomiting and cannabis in Minnesota
The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.
- ✗ No
- LEGAL
- 30-day supply as certif…
- POSSESSION
- $40/yr
- STATE FEE
- 7–30 d
- TIMELINE
Minnesota statute and program
The Minnesota Medical Cannabis Program is the operating authority for Minnesota patient certification. The authoritative legal text is: Minnesota Statutes Chapter 342: Cannabis Regulation (HF 100 of 2023).
What the evidence says about cannabis and Chemotherapy-Induced Nausea and Vomiting
Two oral synthetic cannabinoids (dronabinol and nabilone) are FDA-approved for chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetic therapy. The 2017 NASEM consensus report concluded that there is substantial evidence supporting their effectiveness in adults.
For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Chemotherapy-Induced Nausea and Vomiting page.
How to qualify in Minnesota
The Minnesota Medical Cannabis Program requires the following registration steps for a Chemotherapy-Induced Nausea and Vomiting patient (or any qualifying diagnosis):
- Get a written certification from a Minnesota-licensed practitioner. Under Minn. Stat. §152.22 et seq. (the Medical Cannabis Therapeutic Research Act of 2014, expanded under the 2023 cannabis reform), any Minnesota-licensed physician, advanced practice registered nurse, or physician assistant authorized to prescribe controlled substances may certify a patient. Qualifying conditions include cancer, glaucoma, HIV/AIDS, ALS, MS, seizures, intractable pain, IBD, autism spectrum, obstructive sleep apnea, terminal illness, PTSD, sickle-cell disease, Alzheimer’s, and others under §152.22(14).
- Apply through the Office of Cannabis Management portal. The certifying practitioner submits the written certification electronically to the Minnesota Office of Cannabis Management (OCM). The patient then completes the online patient enrollment with a Minnesota driver license or state ID, a passport-style photograph, and proof of Minnesota residency.
- Pay the $40 state enrollment fee (or $20 reduced fee). The annual Minnesota medical cannabis patient enrollment fee is $40, reduced to $20 for patients enrolled in MinnesotaCare, MA, SSI, or SSDI. The fee covers both the patient and any designated caregivers. Patients receive a digital patient enrollment confirmation through the OCM portal.
- Purchase from a Minnesota medical cannabis distribution location. With the OCM patient enrollment confirmation and a Minnesota ID, patients may purchase from any of the licensed Minnesota medical cannabis distribution locations (operated by the two medical cannabis manufacturers Vireo Health / Green Goods and LeafLine Labs / Rise). Permitted forms include flower (added 2022), capsules, tinctures, topicals, and vape products. Adult-use retail is expected to launch in late 2025 under the 2023 reform; medical patients retain reduced taxation and prioritized inventory.
- State registration fee
- $40
- Physician visit (typical)
- $150–$300
- Certification to card
- 7–30 days
- Out-of-state patients
- Not eligible
- Minors
- Eligible with caregiver
For full Minnesota registration steps, fees, and reciprocity rules, see the Minnesota cannabis-laws page.
ICD-10 code
A certifying physician documenting Chemotherapy-Induced Nausea and Vomiting for the Minnesota medical cannabis program will typically record ICD-10 R11.2 or SNOMED-CT 422587007 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.
Frequently asked questions
Does Minnesota list Chemotherapy-Induced Nausea and Vomiting as a qualifying condition for medical cannabis?
No. Minnesota's qualifying-condition list does not currently include Chemotherapy-Induced Nausea and Vomiting, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Chemotherapy-Induced Nausea and Vomiting in Minnesota have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Minnesota program rules change, so verify the current list with the regulator before drawing a final conclusion.
How do I get a Minnesota medical marijuana card for Chemotherapy-Induced Nausea and Vomiting?
Because Minnesota does not currently list Chemotherapy-Induced Nausea and Vomiting as a qualifying condition, a card for Chemotherapy-Induced Nausea and Vomiting alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Minnesota who is registered with Minnesota Medical Cannabis Program and willing to evaluate Chemotherapy-Induced Nausea and Vomiting cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Minnesota does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.
What does the evidence say about cannabis for Chemotherapy-Induced Nausea and Vomiting?
For Chemotherapy-Induced Nausea and Vomiting, evidence is described as strong (e.g. multiple randomized controlled trials or systematic reviews supporting effect). The mmjnow condition page for Chemotherapy-Induced Nausea and Vomiting lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Chemotherapy-Induced Nausea and Vomiting should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Chemotherapy-Induced Nausea and Vomiting and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Chemotherapy-Induced Nausea and Vomiting; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.
Sources
- Minnesota Statutes Chapter 342: Cannabis Regulation (HF 100 of 2023)accessed May 15, 2026
- Minnesota Office of Cannabis Managementaccessed May 15, 2026
- NORML: Minnesota Lawsaccessed May 15, 2026
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 14, 2026
“Conclusive or substantial evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy-induced nausea and vomiting.”
- NIH NCCIH: Cannabis (Marijuana) and Cannabinoidsaccessed May 14, 2026